NCT03504501

Synaptic Plasticity and Cognitive Function in RASopathies

Improvement of Synaptic Plasticity and Cognitive Function in RAS Pathway Disorders

• Status: Terminated
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 16 (actual)
• Sponsor: Technical University of Munich · Academic / Other
• Sex: All
• Age: 16 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

The project is targeting cognitive impairment, one of the main health problems of patients with RAS pathway disorders. The aim of this study is to translate findings of animal studies to humans. This has been done by the applicants successfully for Lovastatin in Nf1. This result will be transferred to patients with Noonan Syndrome. lamotrigine is most likely a more effective and promising substance improving synaptic plasticity and consecutive cognitive function. It is expected that both substances are improving synaptic plasticity as well as alertness and changes in alertness may be a precondition for improvement of cognition.

Conditions

• Impaired Synaptic Plasticity
• Impaired Cognition

Interventions

Type	Name	Description
DRUG	Lovastatin	oral application prior to transcranial magnetic stimulation intervention
DRUG	Lamotrigine	oral application prior to transcranial magnetic stimulation intervention

Timeline

• Start date: 2019-03-22
• Primary completion: 2023-02-09
• Completion: 2023-10-31
• First posted: 2018-04-20
• Last updated: 2023-11-30

Locations

1 site across 1 country: Germany